期刊论文详细信息
Cells
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions
Katsutoshi Oda1  CarienL. Creutzberg2  Katherine Bennett3  Helen MacKay4  Alexander Reuss5  Kosei Hasegawa6  Anastassia Negrouk7  Paul Speiser8  IainA. McNeish9  David Millan1,10  HansW. Nijman1,11  EliseC. Kohn1,12  TingYan Shi1,13  Delia Mezzanzanica1,14  Suzy Scholl1,15  Marina Bagnoli1,16  AmitM. Oza1,17  Clare Scott1,18  MarkF. Brady1,19  Charlie Gourley2,20 
[1] Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY 14203, USA;Gynecology, University Medical Center Groningen, 9700 RB Groningen, The Netherlands;Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada;Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD 20852, USA;Coordinating Center for Clinical Trials, at the Philipps-University of Marburg, 35043 Marburg, Germany;;Department of Biostatistics &Department of Drug Development and Innovation, Institut Curie, 75005 Paris, France;Department of Gynaecologic Oncology, Medical University Vienna, General Hospital Vienna, 1090 Wien, Austria;Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama 1397-1, Japan;;Department of Medicine, Division of Medical Oncology &;Department of Obstetrics &Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8654, Japan;Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China;Department of Pathology, Queen Elizabeth University Hospital, Glasgow G51 4TR, UK;Department of Radiation Oncology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy;Division of Cancer, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK;Division of Medical Oncology, University of Toronto/Sunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, Canada;European Organisation for Research and Treatment of Cancer (EORTC), 1200 Brussels, Belgium;University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh EH4 2XU, UK;
关键词: translational studies design;    gynecological cancers;    biomarkers definition;    precision medicine;    samples collection;   
DOI  :  10.3390/cells8030200
来源: DOAJ
【 摘 要 】

In the era of personalized medicine, the introduction of translational studies in clinical trials has substantially increased their costs, but provides the possibility of improving the productivity of trials with a better selection of recruited patients. With the overall goal of creating a roadmap to improve translational design for future gynecological cancer trials and of defining translational goals, a main discussion was held during a brainstorming day of the Gynecologic Cancer InterGroup (GCIG) Translational Research Committee and overall conclusions are here reported. A particular emphasis was dedicated to the new frontier of the immunoprofiling of gynecological cancers. The discussion pointed out that to maximize patients’ benefit, translational studies should be integral to clinical trial design with standardization and optimization of procedures including a harmonization program of Standard Operating Procedures. Pathology-reviewed sample collection should be mandatory and ensured by dedicated funding. Biomarker validation and development should be made public and transparent to ensure rapid progresses with positive outcomes for patients. Guidelines/templates for patients’ informed consent are needed. Importantly for the public, recognized goals are to increase the involvement of advocates and to improve the reporting of translational data in a forum accessible to patients.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次